Concepedia

Publication | Open Access

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

DOIFull Paper Access

34

Citations

22

References

2024

Year

Kenneth W. Mahaffey, Katherine R. Tuttle, Mustafa Arici, Florian M.M. Baeres, George L. Bakris, David M. Charytan, David Z.I. Cherney, Gil Chernin, Ricardo Correa‐Rotter, Janusz Gumprecht,
European Heart Journal

Abstract

Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.

References

YearCitations

Page 1